Evidence check: APOA2 in the context of menopause

The role of APOA2 in the context of menopause is not yet scientifically conclusive. APOA2 encodes apolipoprotein A-II, a component of HDL cholesterol. Some GWAS studies suggest that certain variants (e.g., rs5082) may influence weight regulation and lipid response to saturated fat. During menopause, estrogen decline alters lipid metabolism, increasing cardiovascular risk. Whether APOA2 modulates this effect is insufficiently supported. Effect sizes are small, and evidence comes mostly from association studies, not randomized controlled trials. Therefore, direct utility for personalized nutrition in menopause is questionable. Consumer DNA tests that include APOA2 often overstate clinical relevance. A healthy diet with moderate fat intake remains advisable regardless of genotype. Caveat: Results do not replace medical advice, especially in the presence of existing risk factors.